X0306 4 2018-07-06 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001053466 PATRICK DEVAL L C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2018-07-06 4 M 0 15000 28.45 A 15000 D Common Stock 2018-07-06 4 M 0 15000 20.00 A 30000 D Common Stock 2018-07-06 4 M 0 8361 20.00 A 38361 D Common Stock 2018-07-06 4 M 0 4018 3.40 A 42379 D Common Stock 2018-07-06 4 S 0 42379 43.4008 D 0 D Employee Stock Option (right to buy) 28.45 2018-07-06 4 M 0 15000 0.00 D 2027-06-19 Common Stock 15000 0 D Employee Stock Option (right to buy) 20.00 2018-07-06 4 M 0 15000 0.00 D 2025-08-10 Common Stock 15000 0 D Employee Stock Option (right to buy) 20.00 2018-07-06 4 M 0 8361 0.00 D 2025-08-20 Common Stock 8361 239 D Employee Stock Option (right to buy) 3.40 2018-07-06 4 M 0 4018 0.00 D 2025-04-08 Common Stock 4018 5357 D Represents the weighted average sale price of the shares sold ranging from $43.35 to $43.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 20, 2017, subject to the recipient's continued service on the Issuer's Board of Directors, such that this option became fully exercisable on June 20, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer. The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on September 11, 2015, such that this option became fully exercisable on August 11, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer. The shares subject to this option shall vest and become exercisable in 36 equal monthly installments with the first installment on August 23, 2015, such that this option is fully exercisable on July 23, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer. 25% of the shares subject to this option vested and became exercisable on April 8, 2016, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. /s/Lesley Ann Calhoun, as Attorney-in-Fact 2018-07-10